Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients Treated With Chemotherapy for Haematological Cancer
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Jan 15, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a sensory rehabilitation program designed to help patients who have experienced changes in their sense of taste and smell after undergoing chemotherapy for blood cancers like multiple myeloma and lymphoma. The goal is to see if this program can improve these sensory issues, as well as enhance overall quality of life, emotional well-being, and nutrition for participants.
To be eligible for this trial, participants must be between 18 and 75 years old and have noticeable problems with their sense of taste or smell following chemotherapy. They cannot have a history of eating disorders or certain health conditions that might interfere with the trial. Participants will receive support through the sensory rehabilitation program, and they will be asked to complete questionnaires to track their progress. This trial is currently recruiting participants, so if you or someone you know fits the criteria, it might be a good opportunity to explore ways to improve daily living after cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 18 and ≤ 75 years old
- • Patient with olfactory or gustatory disorders
- • Patient who has completed chemotherapy for haematological cancer
- Exclusion Criteria:
- • Eating disorder known prior to anti-cancer treatment, bulimic, anorexic or binge eating disorder (DSM-V criteria)
- • Refusal to sign the free and informed consent
- • Hypersensitivity to one of the components of liposomal sprays (Liposaliva® or liponasal®)
- • COVID + patient in the previous 3 months
- • Performance status ECOG 3 or 4
- • Patient included in another clinical trial modifying taste / olfaction
- • Artificial nutrition post-chemotherapy
- • Known food allergies
- • Having a reading level in French that may interfere with a good understanding of the protocol and the questionnaires
- • Presenting visual or hearing deficits uncorrected to normal and which may affect the proper completion of the questionnaires
- • Patient under curatorship or tutorship.
- • Patient deprived of liberty
- • Pregnant or breastfeeding patient
- • Not be affiliated with a French social security scheme or beneficiary of such a scheme
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Patients applied
Trial Officials
Franciane PAUL, Dr.
Study Director
UH of Montpellier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials